

# PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thy-moglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity

NCT06199427

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 2
<b>Sponsor</b>	Federal Research Institute of Pediatric Hematology, Oncology and Immunology
<b>Enrollment</b>	100 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- Patients aged e 0 months and \< 21 years
- Patients diagnosed with NBS eligible for an allogeneic HSCT
- Signed written informed consent signed by a parent or legal guardian

### Exclusion (1)

- Concomitant severe somatic disease associated with an additional risk of severe complications

## Locations (1 total)

---

HSCT department, Moscow, Russia